文献速递妇科

FDA批准的伴随诊断与另一种检测试剂盒在卵巢癌同源重组缺陷评估中的一致性

Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-01-29

本研究比较了基于Illumina TruSight Oncology 500研究检测的TSO 500 HRD试剂盒与Myriad MyChoice CDx PLUS试剂盒在卵巢肿瘤样本中评估同源重组缺陷(HRD)状态和BRCA突变的一致性。结果显示TSO 500 HRD试剂盒与Myriad试剂盒的HRD阳性率分别为51.2%和49.2%,BRCA突变率分别为27.6%和25.5%,优化后HRD基因组不稳定评分(GIS)的一致性为0.980,非BRCA突变队列为0.976,总体一致性超过93%。

要点

  • TSO 500 HRD试剂盒与Myriad试剂盒检测的HRD阳性率分别为51.2%和49.2%,BRCA突变率分别为27.6%和25.5%。
  • 优化后HRD GIS在全部样本中的一致性为0.980,在非BRCA突变队列中为0.976。
  • 两种试剂盒的总体HRD状态、BRCA分析各组分及HRD GIS检测结果高度一致(>93%)。

核心结论

  • TSO 500 HRD试剂盒与Myriad试剂盒在总体HRD状态、BRCA分析各组分及HRD GIS检测结果上高度一致(>93%),提示TSO 500 HRD试剂盒的分析准确性接近FDA批准的Myriad试剂盒。

研究设计与样本

  • 研究比较了TSO 500 HRD试剂盒(基于Illumina TruSight Oncology 500研究检测的基因组内容,包含BRCA变异识别及Myriad许可的专有算法,并额外检测HRD基因组不稳定评分)与Myriad MyChoice CDx PLUS试剂盒在卵巢肿瘤样本中的检测数据。

主要发现

  • 总体HRD阳性率:TSO 500 HRD试剂盒为51.2%,Myriad试剂盒为49.2%。
  • BRCA突变(有害或疑似有害的BRCA1或BRCA2突变或两者)阳性率:TSO 500 HRD试剂盒为27.6%,Myriad试剂盒为25.5%。
  • 优化后HRD GIS一致性:全部样本为0.980,非BRCA突变队列为0.976。
  • 受试者工作特征曲线下面积:全部样本为0.995,非BRCA突变队列为0.992。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Authors evaluated the performance of a commercially available next-generation sequencing assay kit; this was based on genomic content from Illumina's TruSight™ Oncology 500 research assay that identifies BRCA variants and proprietary algorithms licensed from Myriad and, with additional genomic content, measures the homologous recombination deficiency (HRD) genomic instability score (GIS) in tumor tissue (TSO 500 HRD assay). METHODS: Data from the TSO 500 HRD assay were compared with data from the Myriad MyChoice®CDx PLUS assay (Myriad assay). Prevalence rates for overall HRD status and BRCA mutations (a deleterious or suspected deleterious BRCA1 or BRCA2 mutation or both) and assay agreement rates for HRD GIS and BRCA analysis were assessed in ovarian tumor samples. Pearson correlations of the continuous HRD GIS and analytic sensitivity and specificity were evaluated. RESULTS: The prevalence of overall HRD positivity was 51.2% (TSO 500 HRD assay) versus 49.2% (Myriad assay) and the prevalence of BRCA mutations was 27.6% (TSO 500 HRD assay) versus 25.5% (Myriad assay). After post-processing optimization, concordance of the HRD GIS was 0.980 in all samples and 0.976 in the non-BRCA mutation cohort; the area under the receiver operating characteristic curve was 0.995 and 0.992, respectively. CONCLUSIONS: Comparison between the Illumina and Myriad assays showed that overall HRD status, the individual components of BRCA analysis, and HRD GIS detection results were highly concordant (>93%), suggesting the TSO 500 HRD assay will approach the analytical accuracy of the FDA-approved Myriad assay.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wehn AK, Qiu P, Lunceford J, et al. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer. Gynecol Oncol. 2024. PMID: 38290412. doi:10.1016/j.ygyno.2024.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。